EMA/HMA statement on interchangeability of biosimilars
  Published on October 6, 2022
© EMA 2022

EMA and the Heads of Medicines Agencies (HMA) have recently issued a joint statement confirming that biosimilar medicines approved in the European Union (EU) are interchangeable with their reference medicine or with an equivalent biosimilar.

Interchangeability of biosimilars without additional clinical trials required will improve the global accessibility of biological medicines.

Scroll to Top